Skip to content

The clinical study of the treatment by Granulocyte colony stimulating factor for idiopathic pulmonary fibrosis.

An Open-label, parallel, randomized controlled clinical study of the treatment by Granulocyte colony stimulating factor for idiopathic pulmonary fibrosis.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15005862
Enrollment
Unknown
Registered
2015-01-19
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

treatment group:subcutaneous injection of Granulocyte colony stimulating factor termly
control group:no processing

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Idiopathic pulmonary fibrosis (IPF) patients are diagnosed according to the 2011 ATS / ERS / JRS / ALAT; 2. Male or female without pregnancy,aged during 50 to 80 years old; 3. Have good compliance, willing to exercise in accordance with the program and follow-up with the schedule; 4. Patients were fully informed of the purpose, method and possible discomfort of the test, agree and signed in consent.

Exclusion criteria

Exclusion criteria: 1. Having serious diseases in other system and organ dysfunction; 2. Having malignant tumor; 3. Participating in other clinical trials within three months; 4. Patients with abnormal renal function: Creatinine value > 1.5 times of the upper limit of normal value; 5. Patients with splenomegaly; 6. Patients With diseases of the blood system; 7. Pregnancy, breast-feeding women, planning to pregnant and those who can not take effective contraceptive measures; 8. There is any unsuitable situation for those selected.

Design outcomes

Primary

MeasureTime frame
the score of The St George's;times of hospitalization due to the aggravation;

Secondary

MeasureTime frame
lung function (forced vital capacity, carbon monoxide diffusion capacity, the ratio of first second forced vital capacity to forced vital capacity);The changes of high resolution computed tomography;arterial blood gases(Partial pressure of oxygen partial pressure, carbon dioxide, arterial blood oxygen saturation);indicators related to pulmonary fibrosis;End of treatment of pulmonary fibrosis related events (such as the death toll);results of six-minutes walking test;

Countries

China

Contacts

Public ContactHuiping Li
liw2013@126.com+86 13817389991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026